Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 6/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | PLG | P00747 | 5/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6061407 | 0.85 | PLG (0.44) | PLAUPRSS1PLGF2F10 | |
| Acetic Acid SCHEMBL6509040 | 0.84 | PLAU (0.53) | PLAUPRSS1PLGF2F10 | |
| Acetic Acid SCHEMBL6061981 | 0.83 | PLAU (0.52) | PLAUPRSS1PLGCHEK2F2 | |
| SCHEMBL21017278 | 0.83 | PLAU (0.57) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL6505081 | 0.83 | PLAU (0.46) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL6061283 | 0.82 | F2 (0.49) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL6061587 | 0.82 | PLAU (0.54) | PLAUPRSS1PLGCHEK2F2 | |
| SCHEMBL5401865 | 0.81 | PLAU (0.56) | PLAUPRSS1PLGF2F10 | |
| Hydrochloric Acid SCHEMBL11298806 | 0.81 | PLAU (0.65) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL7879342 | 0.81 | PLAU (0.65) | PLAUPRSS1PLGF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148646-A1 | Dicationic triaryl analogs as anti-protozoan agents | DDT, DDC, DARS1 | PLAU 4116/4885PRSS1 2474/4885PLG 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.